Industry ownership intelligence

Medical Devices insider conviction

Executive and director activity assessed across 83 companies for breadth, transaction quality, clustering, freshness, and directional conviction.

48/100

Balanced insider tape

90/100 confidence
Level
Industry
Evidence window
Latest 90 days
Named insiders
642
Latest evidence
7 Aug 2026

Capital positioning read

Balanced insider tape

Acquisition and disposal evidence is mixed after low-information compensation and derivative activity is separated out.

Wait for clearer clustering

Evidence in favour

  • 126 distinct acquisition events survive duplicate and security-type controls.
  • Participation spans 642 named insiders rather than one filing source.
  • The latest qualifying evidence is fresh, dated 07 Aug 2026.

Decision risks

  • Qualifying disposal events outnumber acquisitions, although disposals receive a lower directional weight.
Conviction48Balanced insider tape
Confidence90Deep evidence
Controlled events489directional common-share events
Company breadth83represented companies
Acquisition value$26.8Mnormalized amount
Disposal value$270.7Mnormalized amount

Flow regime

Twelve-week filing pressure

Shows the cadence and balance of the full filing tape.

15825 May
30901 Jun
16008 Jun
15715 Jun
7922 Jun
11129 Jun
7006 Jul
4213 Jul
3420 Jul
8227 Jul
5303 Aug
010 Aug
AcquisitionsDisposalsScore 48 · Confidence 90

Relative positioning

Industry peer map

Current score with confidence.

Directional balance

Controlled event mix

25.8%acquisition
Acquisition events
126
Disposal events
363
Net value
-$243.9M

Evidence quality

What the filings represent

Common equity1021
Equity compensation301
Options and derivatives231
Other securities10

Decision makers

Role participation

Director886
Other executive252
CEO and chair145
Finance leadership115
Other or unspecified112
Large holder53

Quality controls

Evidence usability

Normalized values
34%
Priced common share
33%
Named insiders
642
Controlled events
489

Auditable evidence

Latest Medical Devices filings

Showing 961 to 990 of 1563.

BVSBioventus Inc
COWDY, PHILIP G.Director
DisposalEquity compensation
Not reportedContext evidence
BVSBioventus Inc
HAWKINS, WILLIAM ADirector
DisposalEquity compensation
Not reportedContext evidence
BVSBioventus Inc
HAWKINS, WILLIAM ADirector
AcquisitionCommon equity
Not reportedContext evidence
BVSBioventus Inc
LADONE, MARY KAYDirector
AcquisitionCommon equity
Not reportedContext evidence
BVSBioventus Inc
LADONE, MARY KAYDirector
DisposalEquity compensation
Not reportedContext evidence
BVSBioventus Inc
MCMURRY-HEATH, MICHELLEDirector
AcquisitionCommon equity
Not reportedContext evidence
BVSBioventus Inc
MCMURRY-HEATH, MICHELLEDirector
DisposalEquity compensation
Not reportedContext evidence
BVSBioventus Inc
NEELS, GUIDO JDirector
AcquisitionCommon equity
Not reportedContext evidence
BVSBioventus Inc
NEELS, GUIDO JDirector
DisposalEquity compensation
Not reportedContext evidence
BVSBioventus Inc
NOHRA, GUY PDirector
DisposalEquity compensation
Not reportedContext evidence
BVSBioventus Inc
NOHRA, GUY PDirector
AcquisitionCommon equity
Not reportedContext evidence
BVSBioventus Inc
STALNECKER, SUSAN MDirector
DisposalEquity compensation
Not reportedContext evidence
BVSBioventus Inc
STALNECKER, SUSAN MDirector
AcquisitionCommon equity
Not reportedContext evidence
BVSBioventus Inc
SUTTER, MARTIN PDirector, 10% Owner
AcquisitionCommon equity
Not reportedContext evidence
BVSBioventus Inc
SUTTER, MARTIN PDirector, 10% Owner
DisposalEquity compensation
Not reportedContext evidence
CERSCerus Corporation
BJERKHOLT, ERICDirector
AcquisitionCommon equity
Not reportedContext evidence
CERSCerus Corporation
GREGORY, DEAN A.Director
AcquisitionCommon equity
Not reportedContext evidence
CERSCerus Corporation
LUCENA, ANNDirector
AcquisitionCommon equity
Not reportedContext evidence
CERSCerus Corporation
NACHTSHEIM, JAMI KDirector
AcquisitionCommon equity
Not reportedContext evidence
CERSCerus Corporation
SHAN, HUADirector
AcquisitionCommon equity
Not reportedContext evidence
CERSCerus Corporation
WITNEY, FRANKDirector
AcquisitionCommon equity
Not reportedContext evidence
CNMDCONMED Corporation
BRONSON, DAVID M.Director
AcquisitionCommon equity
Not reportedContext evidence
CNMDCONMED Corporation
BRONSON, DAVID M.Director
DisposalEquity compensation
Not reportedContext evidence
CNMDCONMED Corporation
COUNCIL, LAVERNE HDirector
AcquisitionCommon equity
Not reportedContext evidence
CNMDCONMED Corporation
COUNCIL, LAVERNE HDirector
DisposalEquity compensation
Not reportedContext evidence
CNMDCONMED Corporation
FARKAS, CHARLESDirector
AcquisitionCommon equity
Not reportedContext evidence
CNMDCONMED Corporation
FARKAS, CHARLESDirector
DisposalEquity compensation
Not reportedContext evidence
CNMDCONMED Corporation
KAYE, MARKDirector
DisposalEquity compensation
Not reportedContext evidence
CNMDCONMED Corporation
KAYE, MARKDirector
AcquisitionCommon equity
Not reportedContext evidence
CNMDCONMED Corporation
SCHWARZENTRAUB, BARBARA JDirector
DisposalEquity compensation
Not reportedContext evidence

Group-level method

Breadth before headline value

Company breadth

A sector or industry score must be supported across companies. One very large filing cannot manufacture broad conviction.

Economic duplicates

Matching company, date, side, security class, share count, and value records are consolidated for the directional calculation.

Evidence hierarchy

Priced common-share activity determines direction. Compensation and derivative records are mapped separately so ownership mechanics remain visible.

Positioning use

The score identifies where insider alignment merits research or where disposal concentration needs review. Price, trend, valuation, and portfolio risk still decide positioning.

Independent market research for education. This classification is not investment advice, a recommendation, a forecast, or an execution instruction.

Evidence context